EMA's Committee for Medicinal Products for Human Use (CHMP) released the opinion on the AstraZeneca COVID-19 vaccine after the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) confirmed its favourable benefit/risk ratio. AIFA therefore revoked the ban on use, allowing the vaccination campaign to resume fully starting from Friday, 19 March at 3pm.

It is confirmed that the administration of two batches of the AstraZeneca vaccine seized by the judicial authority remains suspended, i.e. batch ABV2856 (also subject to the ban on use of March 11) and batch ABV5811 (which instead was not subject to specific measures by AIFA).

The press conference held at 12.00 at the Ministry of Health, attended by AIFA Director General Nicola Magrini, by the Director General for Prevention Giovanni Rezza and by the President of the CSS Franco Locatelli, can be watched here.